{"name":"Hua Medicine","slug":"hua-medicine","ticker":"2552.HK","exchange":"HKEX","domain":"huamedicine.com","description":"Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA for T2D and obesity; in combination with insulin to treat Type 1 Diabetes; second generation glucokinase (GK) inhibitor for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and GK NAM for metabolic disease. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is based in Shanghai, China.","hq":"Shanghai, China","founded":2013,"employees":"328","ceo":"Li Chen","sector":"Diabetes / Endocrinology","stockPrice":3.46,"stockChange":-0.08,"stockChangePercent":-2.26,"marketCap":"$508M","metrics":{"revenue":72649487.77128832,"revenueGrowth":79.8,"grossMargin":56.9,"rdSpend":0,"netIncome":163056266.92197248,"cash":160983338.78976,"dividendYield":0,"peRatio":2.7,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2032-06-01","label":"HMPL-012 patent cliff ($0.0B at risk)","drug":"HMPL-012","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Dorzagliatin tablets","genericName":"Dorzagliatin tablets","slug":"dorzagliatin-tablets","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HMS5552","genericName":"HMS5552","slug":"hms5552","indication":"Type 2 diabetes mellitus","status":"phase_3"}]}],"pipeline":[{"name":"Dorzagliatin tablets","genericName":"Dorzagliatin tablets","slug":"dorzagliatin-tablets","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HMS5552","genericName":"HMS5552","slug":"hms5552","phase":"phase_3","mechanism":"HMS5552 is a glucokinase activator that enhances glucose sensing and insulin secretion in pancreatic beta cells.","indications":["Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[{"date":"2023-06-29","type":"regulatory","headline":"Hua Medicine Announces Positive Phase 2 Results for HMPL-012","summary":"Hua Medicine announced positive Phase 2 results for HMPL-012, a glucokinase activator for the treatment of type 2 diabetes.","drugName":"HMPL-012","sentiment":"positive"},{"date":"2022-03-15","type":"deal","headline":"Hua Medicine Enters into Licensing Agreement with AstraZeneca","summary":"Hua Medicine entered into a licensing agreement with AstraZeneca to develop and commercialize HMPL-012 in certain territories.","drugName":"HMPL-012","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxOMVJSaWVLN05vMnBsMUZsa2FiS1VBbDhXenZMQlJaN0lLMkF6YzdKMDRfNU0zS0NmczJ4QU1GZUNZbzlzZkRiczVHN3N6VURDY2lueVprMUFMSjduSTF1cEtaZU9vcTN6REpoc21yTFpXUDQtSGdwYkNGQ2V4MFd0Nl84cjVsaUZmT3cwR2hJS2I0NktuVHR4b052Vml0blJBVTh3dXBVMDg0VHhGRnR4c05IZkdnaktpUEtqTVZTQ2REXzBVell2YkRVRXhBb0UtX0Zr?oc=5","date":"2026-03-04","type":"regulatory","source":"BioPharma APAC","summary":"Hua Medicine Secures First Glucokinase Activator Approval Outside Mainland China In Hong Kong - BioPharma APAC","headline":"Hua Medicine Secures First Glucokinase Activator Approval Outside Mainland China In Hong Kong","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOYjFwVzhwTk9LLUk2WFdONUVHMjZQZDNEZ1h4WGl2OEsyYnF0bFV2Zk1sSW1mZDQ2ai1OUzVBV0tpY0NLUEcxTlpvRzFTWXppSHRQTDJGbzVrTWZ0R0d0LUFWWmlqdHI1S01ZTHhSZXZ2R0c3d0dvQ2RvVDR0d1RnelV0Z0FvNEpfZVR2Sl8tXy1tdnJHanhLek9ZdFBrMUFsa2pWT3ZUUk5Cc2VGZmlGeTVCMHk?oc=5","date":"2026-03-03","type":"regulatory","source":"The Pharma Letter","summary":"Hua Medicine secures Hong Kong approval for first-in-class diabetes pill - The Pharma Letter","headline":"Hua Medicine secures Hong Kong approval for first-in-class diabetes pill","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNdXIxeExrb2lCRVBrLUdlV1AtNVhyQlhieUM5U1phNlh1NWI2bDc2ZGRNT21lZFNKbUx5WmxwbGxablFGYVAzc1hIbU8xVXZGSW9VcW1FT2lMeTJwbDJ4Z1JxOVl1WGNNWlRON3JRbnM1VTc3YUJObHlJckh3R1VHT0V5b3J0aXBoejBKbV9Lb3FxU3dOUVhLLXQ4V2dhUWZxZi1aM3pNNnI4M3JVN2F0NnVsUGxMSTVqc2NrX3czN1FUTDhMbjBKd2tn?oc=5","date":"2026-03-02","type":"regulatory","source":"TipRanks","summary":"Hua Medicine Wins Hong Kong Approval for Pioneering Diabetes Drug Dorzagliatin - TipRanks","headline":"Hua Medicine Wins Hong Kong Approval for Pioneering Diabetes Drug Dorzagliatin","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9IeEg1SVB1aDlCWlRzUkIzZVpELVJYZUhMcUpCbFlWYkhlbFh1UmtUcktNQ3Zid01DVnE1cm5TbThLUlM4NUdqVjN1U2dhTGN2WnRxS3ZB?oc=5","date":"2017-05-20","type":"pipeline","source":"Yahoo Finance UK","summary":"Luye Pharma Group Ltd. (2186.HK) stock price, news, quote and history - Yahoo Finance UK","headline":"Luye Pharma Group Ltd. (2186.HK) stock price, news, quote and history","sentiment":"neutral"}],"patents":[{"drugName":"HMPL-012","drugSlug":"glucokinase-activator","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Novo Nordisk","Sanofi","Eli Lilly"],"therapeuticFocus":["Diabetes","Endocrinology"],"financials":{"source":"yahoo_finance","revenue":72649485.41318,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":72649485.41318},{"period":"2024-12-31","value":37713815.88884},{"period":"2023-12-31","value":11290917.399699999},{"period":"2022-12-31","value":2593771.77023}],"grossProfit":41319216.12835,"grossProfitHistory":[{"period":"2025-12-31","value":41319216.12835},{"period":"2024-12-31","value":18382043.88148},{"period":"2023-12-31","value":5508246.27198},{"period":"2022-12-31","value":1133218.4295299998}],"rdSpend":21417813.57994,"rdSpendHistory":[{"period":"2025-12-31","value":21417813.57994},{"period":"2024-12-31","value":31700639.67284},{"period":"2023-12-31","value":25281426.68049},{"period":"2022-12-31","value":19090065.90456}],"sgaSpend":41254368.14955,"operatingIncome":-20037141.158579998,"operatingIncomeHistory":[{"period":"2025-12-31","value":-20037141.158579998},{"period":"2024-12-31","value":-51973296.89988},{"period":"2023-12-31","value":-42606890.652839996},{"period":"2022-12-31","value":-35470812.73121}],"netIncome":163056263.38481,"netIncomeHistory":[{"period":"2025-12-31","value":163056263.38481},{"period":"2024-12-31","value":-36866665.47488},{"period":"2023-12-31","value":-31132040.80418},{"period":"2022-12-31","value":-29993221.86739}],"eps":1.1,"epsHistory":[{"period":"2025-12-31","value":1.1},{"period":"2024-12-31","value":-0.25},{"period":"2023-12-31","value":-0.22},{"period":"2022-12-31","value":-0.21}],"cash":160983338.78976,"cashHistory":[{"period":"2025-12-31","value":160983338.78976},{"period":"2024-12-31","value":167978814.50281},{"period":"2023-12-31","value":215298826.77848},{"period":"2022-12-31","value":72310212.57864}],"totalAssets":216611998.34917998,"totalLiabilities":68279173.78737,"totalDebt":44461100.70121,"equity":148332824.56181,"operatingCashflow":-7685959.3055,"operatingCashflowHistory":[{"period":"2025-12-31","value":-7685959.3055},{"period":"2024-12-31","value":-61600568.87982},{"period":"2023-12-31","value":131076482.63959},{"period":"2022-12-31","value":-33914608.62178}],"capex":-1112142.83642,"capexHistory":[{"period":"2025-12-31","value":-1112142.83642},{"period":"2024-12-31","value":-568893.6322},{"period":"2023-12-31","value":-1450531.38034},{"period":"2022-12-31","value":-4048135.0765899997}],"freeCashflow":-8798102.14192,"dividendsPaid":null,"buybacks":null,"employees":328,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.46,"previousClose":3.54,"fiftyTwoWeekHigh":4.95,"fiftyTwoWeekLow":2,"fiftyTwoWeekRange":"2.0 - 4.95","fiftyDayAverage":3.4,"twoHundredDayAverage":3.44,"beta":0.84,"enterpriseValue":391643911.2999475,"forwardPE":-7.4,"priceToBook":2.97,"priceToSales":6.99,"enterpriseToRevenue":5.39,"enterpriseToEbitda":-20.16,"pegRatio":0,"ebitda":-19424327.75892,"ebitdaMargin":-26.7,"freeCashflow":-17546610.90776208,"operatingCashflow":-7685959.3055,"totalDebt":44461099.522155836,"debtToEquity":30,"currentRatio":6.17,"returnOnAssets":-6,"returnOnEquity":254,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":2,"targetMeanPrice":6.2,"targetHighPrice":6.86,"targetLowPrice":5.53,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":13.2,"institutionHeldPercent":27.5,"sharesOutstanding":996519632,"floatShares":661310358,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.27,"epsForward":-0.47,"revenuePerShare":0.5,"bookValue":1.16,"officers":[{"age":61,"name":"Dr. Li  Chen Ph.D.","title":"Founder, CEO & Executive Director"},{"age":49,"name":"Dr. Yi  Zhang M.D., Ph.D.","title":"Senior VP of Pharma Development, Chief Medical Officer – China and Executive Director"},{"age":54,"name":"Mr. Chien Cheng  Lin J.D.","title":"Executive VP, Chief Strategy Officer & Executive Director"},{"age":58,"name":"Dr. Fuxing  Tang Ph.D.","title":"CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA"},{"age":55,"name":"Dr. Changhong  Li Ph.D.","title":"Chief Scientific Officer"},{"age":77,"name":"Mr. Chengde  Wang","title":"Head of IR"},{"age":50,"name":"Mr. Yu  Lu","title":"Vice President of Sales & Marketing"},{"age":45,"name":"Mr. Ying  Xie M.B.A.","title":"VP of Quality Assurance Division & Chief Quality Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.huamedicine.com","phone":"86 21 3810 1800"}}